Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its position in shares of Glaukos Corporation (NYSE:GKOS) by 32.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 355,279 shares of the medical instruments supplier’s stock after acquiring an additional 87,781 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.62% of Glaukos worth $39,336,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. AustralianSuper Pty Ltd increased its holdings in Glaukos by 10.8% during the 3rd quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after acquiring an additional 43,750 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Glaukos by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after acquiring an additional 27,646 shares in the last quarter. Riverbridge Partners LLC boosted its stake in shares of Glaukos by 41.0% during the third quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock valued at $46,454,000 after acquiring an additional 165,673 shares during the last quarter. Holocene Advisors LP boosted its stake in shares of Glaukos by 40.1% during the second quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock valued at $108,030,000 after acquiring an additional 299,118 shares during the last quarter. Finally, TD Asset Management Inc acquired a new position in shares of Glaukos in the third quarter valued at approximately $1,157,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on GKOS. Stifel Nicolaus raised their target price on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Needham & Company LLC boosted their price target on Glaukos from $125.00 to $127.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Truist Financial increased their price target on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Wells Fargo & Company raised their price objective on Glaukos from $122.00 to $135.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, William Blair raised Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and an average price target of $133.69.

Glaukos Stock Up 0.0%

Shares of Glaukos stock opened at $112.68 on Friday. The company has a fifty day moving average price of $111.82 and a 200 day moving average price of $102.51. The stock has a market cap of $6.54 billion, a price-to-earnings ratio of -34.57 and a beta of 0.78. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $130.23. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last issued its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The company had revenue of $143.12 million during the quarter, compared to analysts’ expectations of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.Glaukos’s quarterly revenue was up 35.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.40) EPS. Equities research analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, Director Aimee S. Weisner sold 15,000 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the completion of the transaction, the director directly owned 18,806 shares in the company, valued at approximately $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas William Burns sold 186,945 shares of the business’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $115.00, for a total transaction of $21,498,675.00. Following the completion of the transaction, the chief executive officer owned 153,775 shares in the company, valued at $17,684,125. This represents a 54.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 324,657 shares of company stock valued at $37,692,269. 5.80% of the stock is owned by company insiders.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.